Stock News and Filings Feed


Add MACK
to your dashboard

Mack Trading Co reports standalone net profit of Rs 0.01 crore in the June 2016 quarter

2016-08-13 indiainfoline
Mack Trading Co reports standalone net profit of Rs 0.01 crore in the June 2016 quarter

Columbia Funds Series Trust II Form N-Q

2015-12-29 sec.gov
      OMB APPROVAL     OMB Number: 3235-0578     Expires: January 31, 2016   UNITED STATES Estimated average burden hours per response. . . . 10.5   SECURITIES AND EXCHANGE COMMISSION     Washington, D.C. 20549     FORM N-Q   QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY   Investment Company Act file number 811-21852   Columbia Funds Series Trust II (Exact name of registrant as specified in charter)   50606 Ameriprise Financial Center Minneapolis, MN   5547

COLUMBIA FUNDS SERIES TRUST Form N-Q

2015-12-29 sec.gov
      OMB APPROVAL     OMB Number: 3235-0578     Expires: January 31, 2016   UNITED STATES Estimated average burden hours per response . . . . . . . . . . 10.5   SECURITIES AND EXCHANGE COMMISSION     Washington, D.C. 20549     FORM N-Q   QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY   Investment Company Act file number 811-09645   Columbia Funds Series Trust (Exact name of registrant as specified in charter)   50606 Ameriprise Financial Center Minneapolis,

3
shares
Premarket Biotech Digest: Arrowhead's Potential, KaloBios Delisting, BiondVax Patent

2015-12-28 seekingalpha
Arrowhead could take off in 2016.KaloBios will be delisted from the NASDAQ this week.Biondvax has been granted a patent for its flu vaccine.

2
shares
Premarket Biotech Digest: Celldex's Catalyst, Shire-Baxalta Deal, PSivida Surges

2015-12-24 seekingalpha
Celldex is set up nicely for a bounce-back in 2016.Shire and Baxalta are close to completing a deal says Reuters.PSivida surges on positive data from Phase III trial.

2
shares
Do Hedge Funds Love Merrimack Pharmaceuticals Inc (MACK)?

2015-12-13 insidermonkey
Hedge funds are not perfect. They have their bad picks just like everyone else. Micron, a stock hedge funds have loved, lost 50% during the last 12 months...

Do Hedge Funds Love Ollie’s Bargain Outlet Holdings Inc (OLLI)?

2015-12-13 insidermonkey
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the...

Hercules Technology Growth Capital Form N-2/A

2015-12-12 sec.gov
Amendment No 1. to Form N-2 Table of Contents Index to Financial Statements As filed with the Securities and Exchange Commission on June 8, 2015 Securities Act File No. 333-203511     U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM N-2 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Check appropriate box or boxes)     Pre-Effective Amendment No. 1 Post-Effective Amendment No.

SEASONS SERIES TRUST Form N-CSRS

2015-12-09 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM N-CSR   CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT INVESTMENT COMPANIES   Investment Company Act file number 811-07725   SEASONS SERIES TRUST (Exact name of registrant as specified in charter)   1999 Avenue of the Stars, 27th Floor, Los Angeles, CA   90067-6022 (Address of principal executive offices)   (Zip code)   John T.

Merrimack Pharmaceuticals, Inc. – Value Analysis (NASDAQ:MACK) : November 30, 2015

2015-12-01 capitalcube
Click here to see latest analysisCapitalcube gives Merrimack Pharmaceuticals, Inc. a score of 38.Our analysis is based on comparing Merrimack Pharmaceuticals, Inc. with the following peers – Celgene Corporation, Sanofi Sponsored ADR, Dyax Corp., AVEO Pharmaceuticals, Inc., Geron Corporation, Clovis Oncology, Inc., Cerulean Pharma, Inc., Immunomedics, Inc., Synta Pharmaceuticals Corp. and BioTime, Inc.

Merrimack Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : November 30, 2015

2015-12-01 capitalcube
Click here to see latest analysis*Disclaimer : This is as of previous day’s closing price.Technical IndicatorsBelow is a quick look at 5 technical indicators for Merrimack Pharmaceuticals, Inc.. More studies are available on the Technical Chart.IndicatorSignalClosing Price above/below 50 Day Moving AverageBullishClosing Price above/below 200 Day Moving AverageBearish50 Day Moving Average above/below 200 Day Moving …

VANGUARD VALLEY FORGE FUNDS Form N-Q

2015-12-01 sec.gov
valleyforge_final.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT COMPANY   Investment Company Act file number:   811-58431   Name of Registrant:   Vanguard Valley Forge Funds   Address of Registrant: P.O. Box 2600 Valley Forge, PA 19482   Name and address of agent for service: Heidi Stam, Esquire P.

VANGUARD INSTITUTIONAL INDEX FUNDS Form N-Q

2015-12-01 sec.gov
institutionalindex_final.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT COMPANY   Investment Company Act file number:    811-06093   Name of Registrant:   Vanguard Institutional Index Funds   Address of Registrant: P.O. Box 2600 Valley Forge, PA 19482   Name and address of agent for service: Heidi Stam, Esquire P.

VANGUARD INDEX FUNDS Form N-Q

2015-12-01 sec.gov
index_final.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT COMPANY   Investment Company Act file number:   811-02652   Name of Registrant:   Vanguard Index Funds   Address of Registrant: P.O. Box 2600 Valley Forge, PA 19482   Name and address of agent for service: Heidi Stam, Esquire P.

Vanguard Montgomery Funds Form EX-99.CERT

2015-12-01 sec.gov
certifications.htm - Generated by SEC Publisher for SEC Filing   CERTIFICATIONS   I, F. William McNabb III, certify that:   1. I have reviewed this report on Form N-Q of Vanguard Montgomery Funds;   2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Vanguard Montgomery Funds Form N-Q

2015-12-01 sec.gov
montgomery_final.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT COMPANY   Investment Company Act file number:   811-22114   Name of Registrant:  Vanguard Montgomery Funds   Address of Registrant: P.O. Box 2600 Valley Forge, PA 19482   Name and address of agent for service: Heidi Stam, Esquire P.

FIRST TRUST EXCHANGE-TRADED FUND Form N-Q

2015-12-01 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM N-Q   QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY   Investment Company Act file number 811-21774   First Trust Exchange-Traded Fund (Exact name of registrant as specified in charter)   120 East Liberty Drive, Suite 400 Wheaton, IL 60187 (Address of principal executive offices) (Zip code) W.

RYDEX VARIABLE TRUST Form N-Q

2015-12-01 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM N-Q   QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number 811-08821   Rydex Variable Trust (Exact name of registrant as specified in charter)   805 King Farm Boulevard, Suite 600 Rockville, Maryland 20850 (Address of principal executive offices) (Zip code) Donald C.

VARIABLE INSURANCE PRODUCTS III Form EX-99.CERT

2015-11-30 sec.gov
Form of Certification required from Principal Executive Officer and Principal Financial Officer in connection with each Form N                                                  Exhibit EX-99.CERT I, Kenneth B. Robins, certify that: 1. I have reviewed this report on Form N-Q of Variable Insurance Products Fund III; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the ci

VARIABLE INSURANCE PRODUCTS III Form N-Q

2015-11-30 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number   811-7205   Variable Insurance Products Fund III (Exact name of registrant as specified in charter) 245 Summer St., Boston, Massachusetts 02210 (Address of principal executive offices)       (Zip code) Marc Bryant, Secretary 245 Summer St.

VARIABLE INSURANCE PRODUCTS FUND II Form EX-99.CERT

2015-11-30 sec.gov
Converted by EDGARwiz                                                       Exhibit EX-99.CERT       I, Kenneth B. Robins, certify that: 1. I have reviewed this report on Form N-Q of Variable Insurance Products Fund II; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period co

VARIABLE INSURANCE PRODUCTS FUND II Form N-Q

2015-11-30 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number   811-5511 Variable Insurance Products Fund II  (Exact name of registrant as specified in charter) 245 Summer St., Boston, Massachusetts 02210  (Address of principal executive offices)       (Zip code) Marc Bryant, Secretary 245 Summer St.

2
shares
Premarket Biotech Digest: Gilead Gets A Boost, Zafgen's Beloranib Program, Relypsa Gets FDA Nod

2015-11-29 seekingalpha
Gilead Sciences rose more than 5% on some positive developments.Zafgen provides update on Beloranib program.Relypsa tumbles despite FDA approval for hyperkalemia treatment.

Baxalta’s ONIVYDE NAPOLI-1 Study Sends It to Top of Large-Caps

2015-11-25 marketrealist
The large-cap stocks of the Health Care Select Sector SPDR ETF (XLV) rose marginally with a return of 0.4% on November 24, 2015. XLV’s large-caps outperformed XLV as well as the SPDR S&P 500 ETF (SPY), with returns of 0.3% and 0.15%, respectively.

PharmaEngine Announces the Lancet Publication of the ONIVYDE(TM) Phase 3 NAPOLI-1 Study

2015-11-23 prnewswire
TAIPEI, Taiwan, Nov. 22, 2015 /PRNewswire/ -- PharmaEngine, Inc. (TWO: 4162) announced that The Lancet has...

Fintel IR - Find the Right Investors for Your Company, Instantly!

Fintel IR combines the comprehensive Fintel ownership database with machine learning to provide advanced tools to make investor outreach fast and easy. Learn more now!